New therapeutic strategies for patients with gastrointestinal malignancies using biochemical modulation of fluorouracil.
Allegra
C J
CJ
National Cancer Institute-Navy Medical Oncology Branch, National Naval Medical Center, Bethesda, MD 20889-5105.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000201:enzymology* / Q000556:secondary; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015415:Biomarkers / Q000032:analysis; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D017809:Fatal Outcome; D005472:Fluorouracil / Q000008:administration & dosage / Q000494:pharmacology*; D005492:Folic Acid / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D005493:Folic Acid Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D002955:Leucovorin / Q000008:administration & dosage / Q000494:pharmacology; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000201:enzymology* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use; D012333:RNA, Messenger / Q000032:analysis; D012334:RNA, Neoplasm / Q000032:analysis; D013940:Thymidylate Synthase / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000235:genetics
D015415:Biomarkers; D005493:Folic Acid Antagonists; D016898:Interferon-alpha; D011799:Quinazolines; D012333:RNA, Messenger; D012334:RNA, Neoplasm; C031662:CB 3717; D005492:Folic Acid; D013940:Thymidylate Synthase; D002955:Leucovorin; D005472:Fluorouracil